$CRL

AI 分析

生成於 May 11, 2026

AI Score
58/ 100
Hold$CRL

Charles River Laboratories

$CRLNYSEHealthcareMid-Cap

Charles River provides drug discovery and development services including preclinical and clinical laboratory services.

Market Cap
$10.0B
Revenue (TTM)
$4.0B
-3.0%
Net Income (TTM)
$0.3B
-10.0%
EPS (TTM)
$5.50
P/E Ratio
28.0
Dividend Yield
0.0%
52-Week Range
$155-$275
Beta
1.15
Dimension Scores
Fundamental
56
Technical
56
Sentiment
60
Risk / Reward
62
Momentum
50
FundTechSentRiskMome
Financial Health
Profitability
61moderate
Growth
53weak
Liquidity
70strong
Solvency
58moderate
Efficiency
54moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $CRL

Free · No credit card required

免責聲明: AI 生成的分析僅供教育參考,不構成投資建議。請始終諮詢合格的理財顧問。

探索更多

用 AI 分析任意股票

獲取涵蓋基本面、技術面、情緒面、風險評估和投資論點的結構化研究報告——約 60 秒完成。